Since March, India has reported a dramatic surge in infections, peaking at approximately 400,000 confirmed new COVID-19 cases per day in early May. The prevailing situation is putting a heavy strain on the healthcare system, which in many places is struggling to meet the need for hosppital beds, equipment and pharmaceuticals. Calmark POC - Covid is a platform for rapid testing of the LDH biomarker, which is an important factor in the assessment of the level of care that will be needed for each patient.

The company r2 Hemostasis Diagnostics India Private Ltd is an expert in coagulation and is active throughout India and in neighbouring countries. The reputable company also operates in other areas, including pharma and life sciences research.

"I am delighted and very, very pleased with today's agreement," says Magdalena Tharaldsen, Director International Business Development at Calmark. "Our product will now be registered in India, a process which will be managed by r2 Hemostasis Diagnostics. We will send over the first product sampes shortly."

Calmark POC - Covid is a platform consisting of an instrument and a test cassette for measurement of the lactate dehydrogenase (LDH) biomarker in the blood of COVID-19 patients. Elevated levels of LDH are associated with a higher risk of severe disease and death in COVID-19 patients. The platform can be used in, e.g., emergency rooms and hospital wards to assess the required level of care.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
 

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-06-2021 19:00 CET.